AIM: The aim of the present study was to evaluate the value of transrectal ultrasonography (TRUS) for prostate cancer diagnosis in men with no other indication for biopsy, such as an abnormal digital rectal examination or abnormally high prostate-specific antigen (PSA) levels. MATERIALS AND METHODS: The study cohort contained a total of 104 men aged 41-78 years (median 62.5 years) who had suspicious findings on TRUS. The median prostate volume of the patients was 33.0 ml (range 15.0-90.9) and the serum PSA ranged from 0.2 to 4.0 ng/ml (median 2.5 ng/ml). RESULTS: Of 104 men, 12 (11.5%) were diagnosed with prostate cancer on initial biopsy. The positive predictive value (PPV) was 3.7% for PSA 0.1-1.0 ng/ml, 4.8% for PSA 1.1-2.0 ng/ml, 16.7% for PSA 2.1-3.0 ng/ml and 18.4% for PSA 3.1-4.0 ng/ml. The PPV for cancer with Gleason score 7 or higher was 0.0%, 0.0%, 16.7% and 7.9%, respectively. No statistically significant differences in patient characteristics and biopsy results were found between patients who received only systemic biopsy and those who received systemic plus lesion-directed biopsies. CONCLUSION: The results of this study do not provide a rationale to recommend the additional use of lesion-directed biopsy in patients with suspicious lesions at TRUS but with no other indication for biopsy. Furthermore, our data raise the question of whether serum PSA levels lower than 4.0 ng/ml should be considered normal in Asian men.
AIM: The aim of the present study was to evaluate the value of transrectal ultrasonography (TRUS) for prostate cancer diagnosis in men with no other indication for biopsy, such as an abnormal digital rectal examination or abnormally high prostate-specific antigen (PSA) levels. MATERIALS AND METHODS: The study cohort contained a total of 104 men aged 41-78 years (median 62.5 years) who had suspicious findings on TRUS. The median prostate volume of the patients was 33.0 ml (range 15.0-90.9) and the serum PSA ranged from 0.2 to 4.0 ng/ml (median 2.5 ng/ml). RESULTS: Of 104 men, 12 (11.5%) were diagnosed with prostate cancer on initial biopsy. The positive predictive value (PPV) was 3.7% for PSA 0.1-1.0 ng/ml, 4.8% for PSA 1.1-2.0 ng/ml, 16.7% for PSA 2.1-3.0 ng/ml and 18.4% for PSA 3.1-4.0 ng/ml. The PPV for cancer with Gleason score 7 or higher was 0.0%, 0.0%, 16.7% and 7.9%, respectively. No statistically significant differences in patient characteristics and biopsy results were found between patients who received only systemic biopsy and those who received systemic plus lesion-directed biopsies. CONCLUSION: The results of this study do not provide a rationale to recommend the additional use of lesion-directed biopsy in patients with suspicious lesions at TRUS but with no other indication for biopsy. Furthermore, our data raise the question of whether serum PSA levels lower than 4.0 ng/ml should be considered normal in Asian men.
Authors: P N Brawn; V O Speights; D Kuhl; M Riggs; A M Spiekerman; R G McCord; K S Coffield; D T Stewart; M L Lind Journal: Cancer Date: 1991-10-01 Impact factor: 6.860
Authors: Won Jae Yang; Dong Hyeon Lee; Byung Ha Chung; Jin Seon Cho; Young Deuk Choi; Se Joong Kim; In Rae Cho; Hong Sup Kim; Chun Il Kim; Sung Joon Hong Journal: Urology Date: 2006-02 Impact factor: 2.649
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: W J Catalona; J P Richie; J B deKernion; F R Ahmann; T L Ratliff; B L Dalkin; L R Kavoussi; M T MacFarlane; P C Southwick Journal: J Urol Date: 1994-12 Impact factor: 7.450